Literature DB >> 17389385

Structural insight into substrate specificity of phosphodiesterase 10.

Huanchen Wang1, Yudong Liu, Jing Hou, Meiyan Zheng, Howard Robinson, Hengming Ke.   

Abstract

Phosphodiesterases (PDEs) hydrolyze the second messengers cAMP and cGMP. It remains unknown how individual PDE families selectively recognize cAMP and cGMP. This work reports structural studies on substrate specificity. The crystal structures of the catalytic domains of the D674A and D564N mutants of PDE10A2 in complex with cAMP and cGMP reveal that two substrates bind to the active site with the same syn configuration but different orientations and interactions. The products AMP and GMP bind PDE10A2 with the anti configuration and interact with both divalent metals, in contrast to no direct contact of the substrates. The structures suggest that the syn configurations of cAMP and cGMP are the genuine substrates for PDE10 and the specificity is achieved through the different interactions and conformations of the substrates. The PDE10A2 structures also show that the conformation of the invariant glutamine is locked by two hydrogen bonds and is unlikely to switch for substrate recognition. Sequence alignment shows a potential pocket, in which variation of amino acids across PDE families defines the size and shape of the pocket and thus determines the substrate specificity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17389385      PMCID: PMC1851569          DOI: 10.1073/pnas.0700279104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

Review 1.  Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling.

Authors:  Celine Mehats; Carsten B Andersen; Marcello Filopanti; S L Catherine Jin; Marco Conti
Journal:  Trends Endocrinol Metab       Date:  2002 Jan-Feb       Impact factor: 12.015

Review 2.  Phosphodiesterases in the CNS: targets for drug development.

Authors:  Frank S Menniti; W Stephen Faraci; Christopher J Schmidt
Journal:  Nat Rev Drug Discov       Date:  2006-08       Impact factor: 84.694

3.  Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development.

Authors:  Huanchen Wang; Yudong Liu; Qing Huai; Jiwen Cai; Roya Zoraghi; Sharron H Francis; Jackie D Corbin; Howard Robinson; Zhongcheng Xin; Guiting Lin; Hengming Ke
Journal:  J Biol Chem       Date:  2006-05-30       Impact factor: 5.157

Review 4.  Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use.

Authors:  Andrew T Bender; Joseph A Beavo
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

5.  Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function.

Authors:  Judith A Siuciak; Sheryl A McCarthy; Douglas S Chapin; Remie A Fujiwara; Larry C James; Robert D Williams; Jeffrey L Stock; John D McNeish; Christine A Strick; Frank S Menniti; Christopher J Schmidt
Journal:  Neuropharmacology       Date:  2006-06-12       Impact factor: 5.250

6.  Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity.

Authors:  R X Xu; A M Hassell; D Vanderwall; M H Lambert; W D Holmes; M A Luther; W J Rocque; M V Milburn; Y Zhao; H Ke; R T Nolte
Journal:  Science       Date:  2000-06-09       Impact factor: 47.728

Review 7.  Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside.

Authors:  M C Truss; C G Stief; S Uckert; A J Becker; J Wefer; D Schultheiss; U Jonas
Journal:  World J Urol       Date:  2001-11       Impact factor: 4.226

8.  Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species.

Authors:  Timothy M Coskran; Daniel Morton; Frank S Menniti; Wendy O Adamowicz; Robin J Kleiman; Anne M Ryan; Christine A Strick; Christopher J Schmidt; Diane T Stephenson
Journal:  J Histochem Cytochem       Date:  2006-07-24       Impact factor: 2.479

Review 9.  Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.

Authors:  Y Liu; Y Shakur; M Yoshitake; J Kambayashi Ji
Journal:  Cardiovasc Drug Rev       Date:  2001

Review 10.  Pharmacology of phosphodiesterase-5 inhibitors.

Authors:  J D Corbin; S H Francis
Journal:  Int J Clin Pract       Date:  2002 Jul-Aug       Impact factor: 2.503

View more
  35 in total

1.  Activation of PDE10 and PDE11 phosphodiesterases.

Authors:  Ronald Jäger; Corina Russwurm; Frank Schwede; Hans-Gottfried Genieser; Doris Koesling; Michael Russwurm
Journal:  J Biol Chem       Date:  2011-11-21       Impact factor: 5.157

2.  Computational determination of binding structures and free energies of phosphodiesterase-2 with benzo[1,4]diazepin-2-one derivatives.

Authors:  Bo Yang; Adel Hamza; Guangju Chen; Yan Wang; Chang-Guo Zhan
Journal:  J Phys Chem B       Date:  2010-11-15       Impact factor: 2.991

3.  Structural Asymmetry of Phosphodiesterase-9A and a Unique Pocket for Selective Binding of a Potent Enantiomeric Inhibitor.

Authors:  Manna Huang; Yongxian Shao; Jianying Hou; Wenjun Cui; Beibei Liang; Yingchun Huang; Zhe Li; Yinuo Wu; Xinhai Zhu; Peiqing Liu; Yiqian Wan; Hengming Ke; Hai-Bin Luo
Journal:  Mol Pharmacol       Date:  2015-08-27       Impact factor: 4.436

4.  The Role of Allostery in the Termination of Second Messenger Signaling.

Authors:  Ruth Nussinov; Chung-Jung Tsai
Journal:  Biophys J       Date:  2015-08-03       Impact factor: 4.033

5.  New insights into PDE4B inhibitor selectivity: CoMFA analyses and molecular docking studies.

Authors:  Sara Guariento; Olga Bruno; Paola Fossa; Elena Cichero
Journal:  Mol Divers       Date:  2015-08-20       Impact factor: 2.943

6.  The multiple roles of computational chemistry in fragment-based drug design.

Authors:  Richard Law; Oliver Barker; John J Barker; Thomas Hesterkamp; Robert Godemann; Ole Andersen; Tara Fryatt; Steve Courtney; Dave Hallett; Mark Whittaker
Journal:  J Comput Aided Mol Des       Date:  2009-06-17       Impact factor: 3.686

7.  Structural basis for the catalytic mechanism of human phosphodiesterase 9.

Authors:  Shenping Liu; Mahmoud N Mansour; Keith S Dillman; Jose R Perez; Dennis E Danley; Paul A Aeed; Samuel P Simons; Peter K Lemotte; Frank S Menniti
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-29       Impact factor: 11.205

Review 8.  Epac-selective cAMP analogs: new tools with which to evaluate the signal transduction properties of cAMP-regulated guanine nucleotide exchange factors.

Authors:  George G Holz; Oleg G Chepurny; Frank Schwede
Journal:  Cell Signal       Date:  2007-07-25       Impact factor: 4.315

9.  Identification of lead BAY60-7550 analogues as potential inhibitors that utilize the hydrophobic groove in PDE2A: a molecular dynamics simulation study.

Authors:  Jitendra Kumar; Tarana Umar; Tasneem Kausar; Mohammad Mobashir; Shahid M Nayeem; Nasimul Hoda
Journal:  J Mol Model       Date:  2016-12-13       Impact factor: 1.810

10.  Refolding and kinetic characterization of the phosphodiesterase-8A catalytic domain.

Authors:  Zier Yan; Huanchen Wang; Jiwen Cai; Hengming Ke
Journal:  Protein Expr Purif       Date:  2008-10-19       Impact factor: 1.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.